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Abstract
Background: Dual antiplatelet therapy (DAPT) with aspirin (ASP) and a P2Y12 blocker is currently standard care after
percutaneous coronary intervention (PCI) with stent insertion, and aims to inhibit platelet function in order to prevent
stent thrombosis. The P2Y12 blocker ticagrelor (TIC) has greater antiplatelet effect than the previously used members
of this class, such as clopidogrel. In healthy volunteers, TIC is sufficient to cause strong platelet inhibition, with little
additional effect from ASP. Omission of ASP may improve the safety of antiplatelet regimes by reducing bleeding.
However, the effect of single antiplatelet treatment with TIC, compared to DAPT with TIC + ASP, has not been studied
in detail in patients with coronary artery disease.
Methods: To compare TIC with TIC + ASP, we have initiated a single centre, open-label randomised controlled trial
(TEMPLATE study) in adults receiving DAPT following PCI with a sample size of 110 patients. Patients are invited to join
the study when, as part of standard care, they are due to switch from DAPT (ASP + any P2Y12 blocker) to single
antiplatelet treatment with ASP alone after 6–12 months. Patients are randomised to receive either TIC or TIC + ASP for
4 weeks. All patients then revert to standard care with ASP alone. Blood samples and clinical data are collected at three
study visits: at baseline during treatment with ASP + any P2Y12 blocker (visit 1); approximately 4 weeks after visit 1
during treatment with either TIC or TIC + ASP (visit 2); and approximately 8 weeks after visit 1 when treatment has
reverted to ASP alone (visit 3). The primary outcome is the extent of platelet inhibition, measured by light
transmission aggregation, flow cytometry, flow chamber and plasma biomarker tests. The primary analysis will
compare the extent of platelet inhibition between the TIC and TIC + ASP groups at visit 2, adjusted for baseline
platelet reactivity. Secondary analyses will compare the extent of platelet inhibition at visit 2 with that at visit 3.
Discussion: This is the first study to compare in detail the extent of platelet inhibition in patients who are receiving
TIC compared with TIC + ASP. The study findings will complement larger-scale trials of the clinical efficacy and safety of
TIC compared to TIC + ASP.
Trial registration: ISRCTN registry, identifier ISRCTN84335288. Registered on 23 June 2014.
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Background
Dual antiplatelet therapy (DAPT) with aspirin (ASP) and a
P2Y purinoreceptor (P2Y12) blocker is standard care for
patients with coronary artery disease in several settings,
including after acute coronary syndrome (ACS) and
percutaneous coronary intervention (PCI) with or without
coronary stent insertion [1–3]. The rationale for this treat-
ment is that most adverse cardiac events that occur in
these settings result from the formation of abnormal
platelet aggregates causing coronary artery or stent throm-
bosis. Inhibition of platelets by simultaneously targeting
both the thromboxane A2 pathway (with ASP) and the
P2Y12 receptor pathway (with a P2Y12 blocker) results in
strong platelet inhibition and helps prevent aggregate for-
mation [2]. The intensity of antiplatelet treatment is typic-
ally reduced at 6–12 months following ACS or PCI by
switching patients from DAPT to single-agent treatment
with ASP alone. This ensures strong platelet inhibition in
the highest risk period after ACS or PCI and minimises
the long-term bleeding risk associated with DAPT.
When used in combination with ASP, clopidogrel
(CLOP; the first widely used P2Y12 blocker) reduced the
incidence of major adverse cardiac events compared to
single antiplatelet treatment with ASP [4]. However,
approximately 30% of individuals display incomplete in-
hibition of the platelet P2Y12 receptor pathway with
CLOP, resulting in reduced efficacy [5]. These limitations
have been circumvented by the development of strong
P2Y12 blockers such as ticagrelor (TIC), which give
greater and more consistent inhibition of the P2Y12
receptor pathway compared with CLOP. Accordingly,
TIC in combination with ASP is associated with fewer
major adverse cardiac events than CLOP in combination
with ASP [6].
More recent observations made in experimental
models of platelet inhibition [7] and in observational
studies of healthy volunteers receiving antiplatelet treat-
ments [4] suggest that strong P2Y12 blockers such as
TIC used alone result in a consistent and full platelet in-
hibition, and that little further platelet inhibition is
achieved by the addition of ASP. In response to these
findings, it has been proposed that medication with
strong P2Y12 blockers without additional ASP may be
sufficient to achieve full therapeutic antiplatelet effect in
clinical settings in which DAPT is currently standard
care [8]. Avoidance of ASP may also confer safety bene-
fits because ASP is associated with gastrointestinal
bleeding due to its local effect on gastric mucosa, unre-
lated to the antiplatelet effect [9].
Single antiplatelet treatment with TIC is currently being
evaluated in the GLOBAL LEADERS study, which is a
large, international, multicentre, randomised controlled
trial of TIC versus TIC +ASP following PCI and coronary
stent insertion [10]. However, the main endpoints of this
trial are all-cause mortality or non-fatal myocardial infarc-
tion and bleeding. The GLOBAL LEADERS study does
not include a detailed laboratory evaluation of the phar-
macodynamic effect of the two different treatment
regimes on platelet inhibition.
Aims and objectives
The main aim of the TEMPLATE study is to determine
the extent of platelet inhibition in patients with coron-
ary artery disease achieved with single antiplatelet treat-
ment with TIC compared with DAPT with TIC + ASP.
The secondary aim is to compare the effect of TIC or
TIC +ASP to single antiplatelet treatment with ASP alone.
The study objectives are to perform laboratory mea-
surements of platelet inhibition in patients at the fol-
lowing points of treatment with antiplatelet drugs after
PCI: (i) at the end of DAPT with ASP + any P2Y12
blocker treatment; (ii) after 4 weeks of treatment with
either TIC or TIC + ASP; and, (iii) after all patients are
switched to ASP alone after the study intervention.
Methods
Study design and setting
The TEMPLATE study is a single centre, open-label,
randomised controlled trial of the effects of different
antiplatelet treatments on platelet laboratory test results
in patients who have undergone PCI and coronary stent
insertion at the Bristol Heart Institute (BHI).
Study population
The study population is patients at the BHI who have
been prescribed DAPT as part of standard clinical care
following PCI and coronary stent insertion.
A patient will be eligible for inclusion if: (i) prescribed
DAPT with ASP + any P2Y12 blocker for a minimum
interval of 4 weeks; and (ii) intending to transfer to ASP
after cessation of treatment with ASP + any P2Y12 blocker;
and, (iii) aged over 18 years at the point of randomisation.
Patients will be ineligible if any of the following
apply: (i) contraindication to DAPT; (ii) treatment with
ASP + any P2Y12 blocker after PCI was interrupted or
terminated because of bleeding or increased bleeding risk;
(iii) contraindication to TIC; (iv) pregnancy and or breast
feeding; (v) the patient is a woman of childbearing
potential who is unwilling to use contraception; (vi) the
patient is a man with a spouse or partner with childbear-
ing potential unless the patient is sterilised or has agreed
to use barrier contraceptives.
Concomitant medications which may modify the
therapeutic effect of TIC or which may have their thera-
peutic effect modified by TIC are not absolute exclu-
sions to the study, but will be considered as potential
reasons for exclusion by the enrolling clinician. These
include: (i) strong CYP3A4 inducers (e.g. rifampicin,
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dexamethasone, phenytoin, carbamazepine and pheno-
barbital), (ii) CYP3A4 substrates with narrow therapeutic
indices (e.g. cisapride, ergot alkaloids, simvastatin or lov-
astatin, (iii) digoxin, and (iv) potent P-glycoprotein
inhibitors (e.g. verapamil, quinidine, cyclosporin).
Concomitant medications with a potential adverse
interaction when co-prescribed with ASP will be consid-
ered as potential reasons for exclusion by the enrolling
clinician. These include: some diuretics, probenecid,
heparin, phenindione, antiepileptics such as phenytoin,
warfarin, insulin and sulphonylurea hypoglycaemic
agents, non-steroidal anti-inflammatory drugs, metho-
trexate, corticosteroids, antacids, iron salts, carbonates,
alkali hydroxides and ibuprofen.
Patient approach and study visits
Potentially eligible patients will be identified using hos-
pital databases which record the demographic details of
patients who undergo interventional cardiology proce-
dures at the BHI and the antiplatelet treatment pre-
scribed after the procedure. The first approach will be
an invitation letter and patient information leaflet. Since
most patients in the study population were receiving
DAPT for 6–12 months, this was usually sent by post
approximately 6 weeks before the planned completion of
DAPT. Potentially eligible patients who reply expressing
an interest in taking part will be contacted by telephone
and invited to attend three outpatient study visits at the
BHI. They will be instructed to continue with their exist-
ing DAPT until the first study visit. A study flow dia-
gram is shown in Fig. 1.
At each of three study visits, clinical data will be
collected and an 18 mL venous blood sample will be ob-
tained by peripheral venepuncture for laboratory ana-
lysis. The schedule of data collection is shown in Fig. 2.
All data will be collected on a bespoke database and
stored on a secure server.
Study visit 1
Study visit 1 will occur when a patient would be switch-
ing from DAPT with ASP + any P2Y12 blocker to ASP
alone in the standard clinical care pathway. A member
of the research team will describe the study, answer
questions and confirm eligibility. Eligible patients will be
invited to complete and sign the study consent form.
Randomisation
Allocation to the TIC + ASP group or the TIC group in
a 1:1 ratio will be performed by an authorised member
of the research team using a secure internet-based ran-
domisation system (http://www.sealedenvelope.com/),
using block randomisation with blocks of varying sizes.
Clinicians, research nurses, trial coordinators, pharma-
cists and patients will be aware of the allocation. As the
trial is open label, no code-breaking procedure is re-
quired. Since the costs associated with production of a
placebo medication were prohibitively high, we adopted
a pragmatic open-label design in which the study pa-
tients, their clinicians, research nurse and trials coordin-
ator will not be blinded to treatment allocation. We do
not anticipate this to have a significant impact on trial
results. The laboratory staff will be blinded to group
allocation.
Trial interventions
Patients randomised to the TIC +ASP group will transfer
from ASP + any P2Y12 blocker to ASP 75 mg once per day
plus a loading dose of TIC 180 mg followed by TIC 90 mg
twice per day. Patients randomised to the TIC group will
transfer from ASP + any P2Y12 blocker to a loading dose
of TIC 180 mg followed by TIC 90 mg twice per day. The
study medication will continue to be taken until study visit
2 at 28 days (acceptable range 21–35 days) after enrol-
ment and randomisation. The study medication will be
stored and dispensed by the trial site’s pharmacy in
accordance with Good Clinical Practice. Patients will be
asked to record any missed doses, and to return any
unused medication at their second study visit to ascertain
adherence. Patients will be instructed to take the next
scheduled dose as usual, if they miss a dose.
Study visit 2
Patients will be interviewed by the study team to collect
safety data and to check compliance with the study
medication (Fig. 2). The safety data will include adverse
events potentially associated with the study medication,
the occurrence of major adverse cardiac events and
bleeding, categorised using the Bleeding Academic
Research Consortium (BARC) definitions of bleeding
(Table 1) [11].
All patients will then be transferred to ASP 75 mg
once per day, thereby returning to standard clinical care.
This treatment will continue until study visit 3 which
will be 28 days (acceptable range 21–35 days) after study
visit 2, and thereafter, long-term. Patients who are
unable to attend study visit 2 within 35 days from study
visit 1 will be advised to transfer to ASP 75 mg once per
day at 35 days after study visit 1 and will be invited to
attend for a final study visit at the same time as their
planned study visit 3.
Study visit 3
Patients will be interviewed by the study team to collect
safety data and to check compliance with the prescribed
medication. Patients will then exit the study and will be
instructed to continue ASP 75 mg once per day as per
standard clinical care under the ongoing supervision of
their primary care practitioner (Fig. 2).
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Definition of end of trial
Patients will end their involvement in the study after they
have completed study visit 3, at approximately 8 weeks
after study visit 1. The end of the study is when analyses
of blood samples are completed, data queries are resolved,
the database is locked and the analysis completed.
Loss to follow-up and withdrawals
Each patient has the right to withdraw at any time. In this
event, we will analyse any data already collected, unless
the patient expresses a wish for their samples to be
destroyed and any associated data not to be included in
the analysis. We expect low rates of patient withdrawal
and losses to follow-up because the study interval is only
approximately 8 weeks and requires only three study
visits. It is also unlikely that patients will have to be
withdrawn from their allocated study treatment as the
study intervention (TIC + ASP or TIC) is well tolerated
and is prescribed for only a 4-week period. However, in
the event of a serious adverse event that the investigator
believes may be attributable to the intervention, the study
medication will be discontinued and the patient will be
returned to standard care with ASP 75 mg once daily. The
trial medication may also be discontinued if any contrain-
dicated therapy is initiated whilst the patient is participat-
ing in the trial. Data collected before discontinuation of
trial medication will be included in the analyses.
Laboratory analyses
The blood samples obtained at the three study visits will
be analysed using a panel of platelet function and
biomarker tests in a central laboratory. All laboratory
Fig. 1 Trial schema. Schema showing the recruitment pathway with the number of patients to be recruited, anticipated eligibility, recruitment
and follow-up rates. ASP aspirin, CLOP clopidogrel, TIC ticagrelor
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tests will be performed in accordance with reagent man-
ufacturers’ instructions and with locally generated stand-
ard operating procedures. The following analyses will be
performed:
(i) Light transmission aggregation (LTA) in platelet-
rich plasma (PRP) in response to stimulation
with collagen-related peptide (CRP), adenosine
diphosphate (ADP), arachidonic acid (AA),
thromboxane receptor agonist (U46619)
and thrombin-related activator peptide 6 (TRAP 6).
(ii)Flow cytometry to quantify surface CD62P
expression and PAC-1 binding in unstimulated
platelets and in platelets stimulated with CRP and
TRAP 6.
(iii)Adhesion and aggregation of platelets in whole
blood on a collagen surface under flow conditions.
(iv)Plasma concentrations of soluble CD40 ligand
(sCD40L) and thromboxane B2 (TXB2) to assess
baseline in vivo platelet activation and thromboxane
A2 biosynthesis respectively. These biomarkers will
be measured by enzyme-linked immunosorbent
assay using frozen plasma samples, after the end of
recruitment.
Primary outcome
The primary outcome is the maximum amplitude of the
LTA response to TRAP 6 expressed as a percentage of
the absolute difference in light transmission between
PRP and platelet-poor plasma. This was selected as the
primary outcome since the functional response to TRAP
6 represents the best marker of the overall extent of
platelet inhibition.
Secondary outcomes
The secondary outcomes will be the following laboratory
test results:
(i) Maximum amplitude of the LTA responses to CRP,
ADP, AA and U46619.
(ii)Median fluorescence intensity of anti-P selectin and
PAC-1 binding to platelets in unstimulated platelets
and after stimulation with CRP and with TRAP 6.
(iii)Aggregation and adhesion parameters of platelets
exposed to a collagen surface under flow conditions.
(iv)Plasma concentrations of sCD40L and TXB2.
Sample size
The sample size has been set at 110 patients, which is
sufficient to detect a standardised difference in the
primary outcome between the two study interventions
of 0.35 standard deviations. The sample size has been
calculated with the following assumptions:
1. Correlation between the primary outcome measured
at visit 1 and at visit 2 = 0.5
2. No cross-over anticipated
3. 10% loss to follow-up (i.e. missing outcome data at
visit 2)
DAPT with ASP + any P2Y12 blocker is prescribed as
part of standard current care at the BHI to approxi-
mately 1500 adults per year who undergo PCI and
Fig. 2 Schedule of data collection (SPIRIT)
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coronary stent insertion. We estimate that approxi-
mately 1200 (80%) will complete the prescribed duration
of treatment of 6–12 months. Based on previous obser-
vational studies at the BHI, we conservatively estimate
that the overall recruitment and completion rate will be
approximately 10% of eligible patients. Therefore, we
predict that 110 patients will occur in 14–16 months.
Statistical analysis
The laboratory test results will be expressed as continu-
ous variables. The results for the primary comparison of
the maximum amplitude of the LTA response to TRAP
6 between the TIC + ASP and TIC groups will be
analysed using linear mixed regression. The baseline
(visit 1) and post-intervention values (visit 2) will be
modelled jointly in preference to the pre-randomisation
value being modelled as a covariate to avoid the
necessity either to exclude cases with missing pre-
intervention measures or to impute missing pre-
intervention values. The secondary outcome measures
will be compared similarly.
The study will also enable the extent of platelet inhib-
ition to be described within subjects over time as their
treatment changes (i.e. from visit 1 to visit 2 to visit 3).
Comparative analyses will be on the basis of intention
to treat and mean differences will be quantified with
95% confidence intervals. The width of the individual
confidence intervals for the secondary outcomes will be
adjusted for the number of tests carried out (Bonferroni
correction).
The primary analysis will take place when follow-up and
laboratory analyses are complete for all recruited patients.
No interim or subgroup analyses are planned other than
those outlined above. Safety data will be reviewed regu-
larly by the trial management group who meet at frequent
intervals to discuss trial progress. During these meetings
the rate of adverse events in the study population will be
monitored against the anticipated rate of events that are
expected for the target population.
Research approval
Research ethics approval and clinical trial authorisation
were granted in October 2014 by the South-Central
Oxford A Research Ethics Committee (reference 14/SC/
1309) and the Medicines and Healthcare Regulatory
Agency (EUDRACT No. 2013-002734-20) respectively.
The trial is managed by the Clinical Trials and
Evaluation Unit Bristol (CTEU Bristol) and sponsored by
the University Hospitals Bristol NHS Foundation Trust
(www.uhbristol.nhs.uk/research-innovation/). Trial gov-
ernance is through the sponsor’s standard operating pro-
cedures. The trial is registered as ISRCTN84335288 and
conforms to SPIRIT guidelines (see Fig. 2 and Additional
file 1: SPIRIT checklist).
Changes to the protocol since first approved
There have been three substantial amendments made to
the protocol since it was first approved. The first amend-
ment was approved in May 2015 and incorporated
minor clarifications in addition to the new recommenda-
tions from the European Society of Cardiologists. These
recommendations led to a change in duration of stand-
ard DAPT specified in the protocol, from 12 months to
between 6 and 12 months after PCI and insertion of a
drug-eluting stent; this change increased the pool of
eligible patients.
The second amendment to the protocol was approved
in August 2015, removing the plan to establish a Data
Monitoring and Safety Committee (DMSC). This change
was made because, on review of the study design, it be-
came apparent that the study would not benefit from a
Table 1 Bleeding Academic Research Consortium (BARC)
definitions
Class Definition
Type 0 No bleeding.
Type 1 Bleeding that is not actionable and does not cause the patient
to seek unscheduled performance of studies, hospitalisation, or
treatment by a healthcare professional; may include episodes
leading to self-discontinuation of medical therapy by the patient
without consulting a healthcare professional.
Type 2 Any overt, actionable sign of haemorrhage (e.g. more bleeding
than would be expected for a clinical circumstance, including
bleeding found by imaging alone) that does not fit the criteria
for type 3, 4, or 5 but does meet at least one of the following
criteria: requiring nonsurgical, medical intervention by a
healthcare professional, leading to hospitalisation or increased
level of care, prompting evaluation.
Type 3a Overt bleeding plus haemoglobin drop of 3 to < 5 g/dL,
corrected for transfusion (provided haemoglobin drop is
related to bleed) OR any transfusion with overt bleeding.
Type 3b Overt bleeding plus haemoglobin drop < 5 g/dL, corrected for
transfusion (provided haemoglobin drop is related to bleed) OR
cardiac tamponade. Bleeding requiring surgical intervention for
control (excluding dental/nasal/skin/haemorrhoid) OR bleeding
requiring intravenous vasoactive agents.
Type 3c Intracranial haemorrhage (does not include microbleeds or
haemorrhagic transformation, does include intraspinal)
Subcategories confirmed by autopsy or imaging or lumbar
puncture OR intraocular bleed compromising vision.
Type 4 Coronary artery bypass graft (CABG)-related bleeding OR
perioperative intracranial bleeding within 48 h OR reoperation
after closure of sternotomy for the purpose of controlling
bleeding OR transfusion of ≥ 5 U whole blood or packed red
blood cells within a 48 h period (cell saver product are not
included) OR chest tube output ≥ 2 L within a 24-h period.*
Type 5a Probable fatal bleeding; no autopsy or imaging confirmation
but clinically suspicious.
Type 5b Definite fatal bleeding; overt bleeding or autopsy or imaging
confirmation
*If a CABG-related bleed is not adjudicated as at least a type 3 severity event,
it will be classified as not a bleeding event. If a bleeding event occurs with a
clear temporal relationship to CABG (i.e. within a 48-h time frame) but does
not meet type 4 severity criteria, it will be classified as not a bleeding event
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DMSC. Instead, the safety data are being reviewed
closely by the trial management group and the Steering
Committee for Cardiovascular Studies, a subgroup of
the University Hospitals Bristol NHS Foundation Trust
Cardiovascular Research Board.
The third amendment was approved in September
2016. This amendment widened the inclusion criteria
from receiving ASP + CLOP for 6–12 months to receiv-
ing ASP + any P2Y12 blocker for 6–12 months. This wid-
ening of the inclusion criteria was made to enhance
study enrolment because shortly after starting the study,
the institutional standard care changed from using
CLOP as the preferred P2Y12 blocker, to other P2Y12
blockers for some patient subgroups. After this amend-
ment, the enrolment rate increased to that predicted in
the original study design.
Discussion
The TEMPLATE study design will enable unbiased com-
parison of the effects of TIC versus TIC + ASP on plate-
let activity in patients with coronary artery disease. It
will also enable a longitudinal comparison of the effects
TIC and TIC + ASP with the effects of ASP alone in the
same patients. The laboratory tests selected for this
study will enable measurement of functional platelet re-
sponses to a panel of activating agonists using LTA, flow
cytometry and flow chamber tests, selected to measure
the extent of inhibition of the multiple platelet activation
pathways. We will also measure the extent of baseline
platelet activity by testing unstimulated platelets by flow
cytometry and with the soluble platelet activation bio-
marker tests. Together, these data will provide a compre-
hensive description of the overall pharmacodynamic
effects of the different antiplatelet treatments. This in-
formation has not been reported previously in cohorts of
patients with coronary artery disease receiving TIC or
TIC + ASP. To our knowledge, there are no similar pre-
vious studies in this patient group that have evaluated
the pharmacodynamic effect of monotherapy with other
P2Y12 blockers, including CLOP.
The TEMPLATE study design allows the information to
be obtained in a low-risk setting. We are enrolling
patients at the point in the standard clinical care pathway
when there is a transition from DAPT to single-
antiplatelet treatment with ASP, typically at 6 to 12 months
after the PCI procedure. This is after the interval of great-
est risk of major adverse cardiac events and abnormal
bleeding following PCI [12]. Furthermore, the duration of
exposure to the study treatment (i.e. either TIC or TIC
+ ASP) is only 4 weeks, which will minimise the likeli-
hood of adverse events attributable to the study drugs.
The short overall study participation of 8 weeks during
which there are only three study visits should facilitate
study delivery and minimise patient drop-out.
The main benefit of the TEMPLATE study is that the
findings will provide evidence to either support or refute
the hypothesis that TIC monotherapy enables platelet
inhibition to the same extent as dual therapy with TIC +
ASP. This is significant clinically because abnormal bleed-
ing is a major complication of all antiplatelet therapy, but
particularly of ASP which adversely affects gastric mucosa,
increasing the risk of gastrointestinal bleeding [9]. If the
findings of the TEMPLATE study indicate no difference in
platelet inhibition between the TIC treatment group and
the TIC +ASP treatment group, then this would support
avoidance of ASP in this patient group, potentially confer-
ring a safety advantage. This is also part of the rationale of
the large-scale GLOBAL LEADERS randomised con-
trolled trail (NCT01813435) of 16,000 participants in
which the study group receive TIC + ASP for 1 month
after PCI and coronary stent insertion followed by TIC
monotherapy for a further 23 months. The control group
is DAPT with TIC + ASP or CLOP +ASP for 12 months
[10]. The outcomes of the GLOBAL LEADERS study are
all-cause mortality or non-fatal new Q-wave myocardial
infarction (composite primary outcome) and bleeding
(secondary outcome), but do not include pharmacody-
namic measures of the effect of the different antiplatelet
regimes. We anticipate that reporting of TEMPLATE
study results in a peer-reviewed publication will precede
reporting of the GLOBAL LEADERS study results and
that our results will assist interpretation and help inform
future treatment guidelines.
Study status
The trial opened to recruitment in December 2015 with
the first patient recruited in January 2016. Recruitment
is ongoing.
Trial steering committee members
The Trials Steering Committee comprises a consultant
anaesthetist, interventional consultant cardiologist and a
consultant cardiac surgeon.
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 123 kb)
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purinoreceptor 12; PCI: Percutaneous coronary intervention; PRP: Platelet-
rich plasma; sCD40L: soluble CD40 ligand (a soluble plasma biomarker of
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